Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

734 results about "Squalene" patented technology

Squalene is a natural organic compound originally obtained for commercial purposes primarily from shark liver oil (hence its name, as Squalus is a genus of sharks), although plant sources (primarily vegetable oils) are now used as well, including amaranth seed, rice bran, wheat germ, and olives. Yeast cells have been genetically engineered to produce commercially useful quantities of "synthetic" squalane.

Mycoplasma hyopneumoniae bacterin vaccine

The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA. In another embodiment, the invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.
Owner:ZOETIS SERVICE LLC

Schizochytrium limacinum and method or fermenting and producing DHA (Docosahexaenoic Acid) grease utilizing high density of schizochytrium limacinum

The invention belongs to the field of microbial fermentation engineering, and discloses schizochytrium limacinum (Aurantiochytrium sp.SD116). The schizochytrium limacinum is stored in China Microbial Culture Collection Administration Committee General Microbial Center with a number of CGMCC No: 6208), and a method for fermenting and producing DHA (Docosahexaenoic Acid) grease utilizing high density of the schizochytrium limacinum. According to the schizochytrium limacinum and the method disclosed by the invention, a bacterial strain fermenting condition is optimized based on element supply and a fermenting control angle, a carbohydrate supplementation operation is carried out, therefore, high-density fermentation is achieved, dry cell weight finally reaches 70.43g/L, grease content reaches 50.1g/L, DHA occupies more than 35% of total content of fatty acid; moreover, bioactive substances such as beta-carotene, astaxanthin and squalene are contained. The complete set of technology is convenient to operate; higher biomass liveweight and DHA content can be obtained; fermenting cost can be reduced; and the method is suitable for industrial fermenting production.
Owner:QINGDAO INST OF BIOENERGY & BIOPROCESS TECH CHINESE ACADEMY OF SCI

Method for extracting high-purity squalene by taking olive oil as raw material

The invention relates to a method for extracting high-purity squalene by taking olive oil as a raw material. A technological route formed by adopting a secondary molecular distillation and silica gel column chromatography is as follows: an olive oil unsaponifiable substance is taken, squalene is separated and purified by using two stages of molecular distillation, primary molecular distillation is carried out under the conditions of the evaporation surface temperature of 100 to 200 DEG C, the systemic pressure of 0.001 to 0.01mbar and the scraping film rotor speed of 150 to 300rpm, and secondary molecular distillation is carried out to the obtained distillate; the secondary molecular distillation is carried out under the conditions of the evaporation surface temperature of 150 to 300 DEG C, the systemic pressure of 0.001 to 0.01mbar and the scraping film rotor speed of 200 to 350rpm, and the obtained distillate is a squalene crude product; ethyl acetate-normal hexane with different concentrations is used as a mobile phase to carry out gradient elution, the obtained eluent is collected according to time and a solvent is evaporated, the same fractions are merged through chromatographic detection, and the high-purity squalene can be obtained, wherein the content of the raw material olive oil of the squalene is enhanced from 3.6% to about 98%; and especially, by considering the requirement of industrialized production to select an extraction condition especially, the large-scale production of the squalene taking the olive oil as the raw material can be realized.
Owner:JIANGSU ZODIAC MARINE BIOTECH

Mycoplasma hyopneumoniae bacterin vaccine

The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably Carbopol, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as Pluronic®. The vaccine composition may optionally include a preservative, preferably thimerosol and / or EDTA. In another emodiment, the invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.
Owner:ZOETIS SERVICE LLC

Method for extracting squalene by using camellia oleosa seeds as raw materials and tea oil and squalene soft capsules

The invention discloses a method for extracting squalene by using camellia oleosa seeds as raw materials and tea oil and squalene soft capsules and relates to the technical field of biomedicine. The extraction method comprises the following process flows of material preparation, grinding, leaching, concentration, methyl esterification, complexant-borax reaction, macroporous resin chromatographic separation and purification, concentration, extraction, washing, concentration, preparation of squalene crude oil and supercritical carbon dioxide extraction, so that squalene essential oil with the squalene content of more than or equal to 80 percent is obtained. The tea oil and squalene soft capsules are prepared from the following raw materials in percentage by weight: 87 to 90 percent of squalene essential oil with the squalene content of more than or equal to 80 percent, 3 to 5 percent of polyethylene glycol 400, 2 to 3 percent of beewax and 2 to 5 percent of phospholipid. The raw material resources are wide. The prepared tea oil and squalene soft capsules not only can be used for medicine, but also can be used for food therapy, are particularly suitable for administration of treatment and food therapy of patients suffering from hepatitis, fatty liver, acute and chronic inflammation, tumor, chemotherapy, diabetes mellitus and cardio-cerebrovascular disease and have no toxic or side effects.
Owner:李文东
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products